OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Leslie on Current Treatment Options for Relapsed/Refractory MCL

July 23rd 2020

Lori A. Leslie, MD, discusses current treatment options for patients with relapsed/refractory mantle cell lymphoma.

Dr. Shapiro on the Utility of Complete Lymph Node Dissection in Melanoma

July 23rd 2020

Richard L. Shapiro, MD, discusses the utility of complete lymph node dissection in melanoma.

Dr. Mesa on Rechallenging With JAK Inhibitor Therapy in MPNs

July 23rd 2020

Ruben A. Mesa, MD, discusses the potential clinical benefit of rechallenging with JAK inhibitor therapy in patients with myeloproliferative neoplasms.

Dr. Ahn on the KEYNOTE-177 Trial in Newly Diagnosed MSI-H/dMMR mCRC

July 23rd 2020

Daniel H. Ahn, DO, discusses ​updated findings from the ​phase 3 KEYNOTE-177 trial in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer.

Dr. Davids on the Potential Utility of Frontline Ibrutinib/Umbralisib in CLL and MCL

July 22nd 2020

Matthew S. Davids, MD, MMSc, discusses the potential utility of moving the combination of ibrutinib and umbralisib into the frontline setting of chronic lymphocytic leukemia and mantle cell lymphoma.

Dr. Stenzl on Future Research With Enzalutamide in Prostate Cancer

July 22nd 2020

Arnulf Stenzl, MD, discusses future research efforts with enzalutamide in prostate cancer.

Dr. Arend on Unmet Needs in Platinum-Resistant Ovarian Cancer

July 22nd 2020

Rebecca C. Arend, MD, discusses the unmet needs in of patients with platinum-resistant ovarian cancer.

Dr. Komrokji on the Current Treatment Landscape in MDS

July 21st 2020

Rami Komrokji, MD, discusses the current treatment landscape in myelodysplastic syndrome.

Dr. Leslie on the Encouraging Evolving Treatment Landscape in MCL

July 21st 2020

Lori A. Leslie, MD, discusses the encouraging evolving treatment landscape in mantle cell lymphoma.

Dr. Shaughnessy on the Emergence of CAR T-Cell Therapy in Hematologic Malignancies

July 21st 2020

Paul J. Shaughnessy, MD, discusses the emergence of CAR T-cell therapy in hematologic malignancies.

Dr. O’Malley on the Activity of Mirvetuximab Soravtansine in Ovarian Cancer

July 21st 2020

David O'Malley, MD, discusses the activity of ​the investigational antibody-drug conjugate mirvetuximab soravtansine in ovarian cancer.

Dr. Chandra on the Incidence of Targetable Mutations in Melanoma

July 21st 2020

Sunandana Chandra, MD, MS, discusses the incidence of targetable mutations in melanoma.

Dr. Leslie on the Role of BTK Inhibitors in Relapsed/Refractory MCL

July 20th 2020

Lori A. Leslie, MD, discusses the role of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Dr. Costello on Sequencing Challenges in Multiple Myeloma

July 20th 2020

Caitlin Costello, MD, discusses sequencing challenges in multiple myeloma.

Dr. Roué on ​the Next Steps ​With TG-1701 in MCL

July 20th 2020

Gaël Roué, PhD, senior scientist at Josep Carreras Leukaemia Research Institute, discusses the next steps with the investigational BTK inhibitor TG-1701 in mantle cell lymphoma.

Dr. Shore on the Tolerability of Darolutamide in Nonmetastatic CRPC

July 20th 2020

Neal D. Shore, MD, FACS, discusses the safety and tolerability benefits of darolutamide in men with nonmetastatic castration resistant prostate cancer.

Dr. Al-Sawaf on Continual MRD Assessment ​After Venetoclax/Obinutuzumab in CLL

July 20th 2020

Othman Al-Sawaf, MD, discusses ongoing minimal residual disease assessment for patients in the phase 3 CLL14 study with chronic lymphocytic leukemia.

Dr. Davids on the Design of the Phase 3 UNITY Trials in Relapsed/Refractory CLL and MCL

July 17th 2020

Matthew S. Davids, MD, MMSc, discusses the design of the UNITY trials in patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Dr. Ahn on Advancing Actionable Alterations in CRC

July 17th 2020

Daniel H. Ahn, DO, discusses advancing actionable alterations in colorectal cancer.

Dr. Moore on Unmet Clinical Needs in Platinum-Resistant Ovarian Cancer

July 17th 2020

Kathleen Moore, MD, discusses the unmet clinical needs in platinum-resistant ovarian cancer.

NEXT PAGE
PREVIOUS PAGE